Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

13.04 -0.10 (-0.78%)
Streaming Delayed Price Updated: 10:59 AM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TransCode Therapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Nasdaq Drops 75 Points; Crude Oil Down 2%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping 75 points on Wednesday. 
Via Benzinga
Fusion Fuel (HTOO) Stock Is Up 11% on HUGE Deal News
Fusion Fuel (HTOO) stock is heading higher on Wednesday after the company secured a deal with the Portuguese government. 
Via InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?
TransCode Therapeutics (RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why iBio Shares Are Trading Lower By Around 48%; Here Are 23 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 71.3% to $0.7190 in pre-market trading after the company reported withdrawal of registration statement. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday! 
Via InvestorPlace
TransCode Therapeutics Announces Withdrawal of Registration Statement
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning! 
Via InvestorPlace
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END 
Via FinancialNewsMedia
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process... 
Via Benzinga
What Is Going on With Bionano Genomics (BNGO) Stock Today?
Bionano Genomics (BNGO) stock is rising higher on Wednesday after providing an update on its Long String VANTAGE product. 
Via InvestorPlace
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... 
Via Benzinga
Why Is TransCode Therapeutics (RNAZ) Stock Up 30% Today?
RNAZ stock is powering higher today as TransCode Therapeutics cracks the code to an RNA-based cancer treatment. 
Via InvestorPlace
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate... 
Via Benzinga
TransCode Therapeutics Shares Shoot Higher After Encouraging Preclinical Data From Lead Cancer Candidate
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 47.9% to $0.31 during Wednesday's pre-market session. The company's market cap stands at $11.8 million. 
Via Benzinga
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
Study provides additional support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.